Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

• Type of Material: Article
• Authors: Radhakrishnan Ramchandren, University of Tennessee; Eva Domingo-Domenech, Hospital Duran i Reynals; Antonio Rueda, Costa del Sol Hospital; Marek Trneny, Charles University Prague; Tatyana A. Feldman, John Theurer Cancer Center; Hun Ju Lee, University of Texas MD Anderson Cancer Center; Mariano Provencio, Hospital Universitario Puerta de Hierro; Christian Sillaber, Medical University of Vienna; Jonathon Cohen, Emory University; Kerry J. Savage, British Columbia Cancer Centre for Lymphoid Cancer; Wolfgang Willenbacher, Innsbruck University Hospital; Azra H. Ligon, Brigham and Women’s Hospital; Jing Ouyang, Dana Farber Cancer Institute; Robert Redd, Dana Farber Cancer Institute; Scott J. Rodig, Dana Farber Cancer Institute; Margaret A. Shipp, Dana Farber Cancer Institute; Mariana Sacchi, Bristol‐Myers Squibb; Anne Sumbul, Bristol‐Myers Squibb; Philippe Armand, Dana Farber Cancer Institute; Stephen M. Ansell, Mayo Clinic
• Language: English
• Date: 2019-08-10
• Publisher: American Society of Clinical Oncology
• Publication Version: Final Published Version
• Copyright Statement: © 2019 by American Society of Clinical Oncology
• Final Published Version (URL): http://dx.doi.org/10.1200/JCO.19.00315
• Title of Journal or Parent Work: JOURNAL OF CLINICAL ONCOLOGY
• Volume: 37
• Issue: 23
• Start Page: 1997
• End Page: 2007
• Grant/Funding Information: Supported by Bristol-Myers Squibb, which also funded medical writing support. Also supported by the Center for Immuno-Oncology of the Dana-Farber Cancer Institute (S.J.R.), National Cancer Institute Grant No. R01 CA161026 (M.A.S.), and the Miller Family Fund (M.A.S.).; Medical writing and editorial support, under the direction of the authors, were provided by Adam Gill at Caudex and were funded by Bristol-Myers Squibb. The views expressed in this article are the authors’ own and not an official position of Bristol-Myers Squibb or the authors’ respective institutions.
• Research Categories: Health Sciences, Immunology; Health Sciences, Oncology

Abstract

Nivolumab, an anti–programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin lymphoma (cHL). We report results from Cohort D of the CheckMate 205 trial, which assessed nivolumab monotherapy followed by nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed cHL.